Compare Abbott Laboratories (ABT) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs D Wave Quantum Inc — how do they compare? Abbott Laboratories trades at $110.01 (market cap $187.95B), while D Wave Quantum Inc trades at $20.31 (market cap $7.53B). The key difference: Abbott Laboratories is far larger — about 25× D Wave Quantum Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| ABT | QBTS | |
|---|---|---|
Market Cap | $187.95B | $7.53B |
Sector | Health | Technology |
52-Week High | $136.62 | $44.78 |
52-Week Low | $82.57 | $12.98 |
Enterprise Value | $214.96B | $7.04B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
QBTS trades at $20.55, up 1.78% today, with a bearish technical signal despite 100% analyst buy ratings. The stock shows extreme valuation with a P/S of 583.84 and negative profitability, including a net income margin of -2,001.59% for 2026. Recent Q2 2026 earnings missed revenue and EPS estimates, though bookings surged 1,120%, highlighting growth potential amid financial strain. Cash flow trends indicate heavy investment outlays, with net cash flow turning negative in 2026.
Outlook remains speculative; the consensus price target of $38.29 offers significant upside, but high execution risks persist. Investors face volatility from unproven commercial scaling, reliance on financing, and competitive quantum computing pressures. The stock's appeal hinges on future revenue conversion from bookings, making it suitable for risk-tolerant investors betting on long-term quantum adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
